Merck Receives FDA Approval of Hep C Drug ZEPATIER; To Cost $54,600/Patient for 12-Week Course

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) ...